Financial Impact Ranking
Each of the companies in the VV-Good Index are listed here in order of their financial performance.
Responsible management of companies also includes long -term consideration of financial decisions.
With key issues facing the sector such as counterfeit drugs, the patent cliff and the pricing of drugs, combined with the traditional time lag to bring new drugs to market, innovative approaches to growth can foster new ways of accessing new markets.
| Company Name | Financial Impact Score | Company Ranking |
|---|---|---|
| Sanofi | 0.38 (Prev): 8 | 7 |
| Roche | 0.37 (Prev): 7 | 8 |
| Pfizer | 0.35 (Prev): 9 | 9 |
| Novartis | 0.53 (Prev): 4 | 2 |
| Merck | 0.40 (Prev): 2 | 6 |
| Johnson and Johnson | 0.57 (Prev): 1 | 1 |
| GlaxoSmithKline | 0.49 (Prev): 3 | 3 |
| Bayer HealthCare | 0.45 (Prev): 5 | 5 |
| AstraZeneca | 0.46 (Prev): 6 | 4 |
| Abbott Laboratories | 0.30 (Prev): 10 | 10 |